Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Recurrence 9Burkitt Lymphoma 7Neoplasms, Plasma Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Immunoglobulin Light-chain Amyloidosis 5Hodgkin Disease 4Lymphoma, T-Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Lymphoma, T-Cell, Cutaneous 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Glioblastoma 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Astrocytoma 2Amyloidosis 2Waldenstrom Macroglobulinemia 1Vascular Diseases 1Uveal Melanoma 1

Interventions

Bortezomib 3filanesib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Lenalidomide 2Dexamethasone 2sargramostim 1montanide ISA 51 1merphos 1liposomal doxorubicin 1ixazomib 1itacitinib 1incomplete Freund's adjuvant 1fludarabine phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Steroids 1Stem Cell Transplantation 1Sirolimus 1Proteasome Inhibitors 1Methotrexate 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Plasma Cell × Calcium Dobesilate × Clear all
NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

City of Hope Medical Center

Phase 1 Withdrawn
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡